Peginterferon beta-1a not checked
Biogen · BIIB017 · PEGylated Interferon Beta-1a
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- Interferon beta FDA class
- Tested for
- Multiple Sclerosis, Relapsing-Remitting
- Main trialPhase 3
- “This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.”In the company’s words, NCT03958877 on ClinicalTrials.gov
- Other names
- BIIB017 · PEGylated Interferon Beta-1a · Plegridy · PEG IFN β-1a
Other drugs for Multiple Sclerosis, Relapsing-Remitting
Coming up1
- 20 May 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 20 May 2027 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | |
| Phase 4Completed | 2 Oct 2017 | Plegridy Satisfaction Study in Participants | |
| Phase 3Terminated | 21 Jul 2022 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants | |
| Phase 3Authorised | not given | DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis | |
| Phase 3Authorised | not given | DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS | |
| Phase 3Authorised | not given | STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026